CompletedPhase 3

Documentation of Efficacy of Intralymphatic Allergen Immunotherapy

Denmark, Sweden450 participantsStarted 2020-02-01

Plain-language summary

Investigation of the clinical efficacy of 3 intralymphatic injections with grass pollen extract into inguinal lymph nodes on combined symptom-medication scores during grass pollen season in grass pollen allergic patients compared to placebo

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * moderate-severe grass pollen allergic rhinoconjunctivitis * positive skin prick test for grass pollen extract Exclusion Criteria: * significant mugwort allergy * previous AIT for grass pollen allergy * uncontrolled non-allergic upper airways disease * uncontrolled asthma * planned depot steroid injections during season * uncontrolled autoimmune diseases * active malignancies * uncontrolled other severe condition, including psychiatric diseases

What they're measuring

Combined symptom and medication score, cSMS

Timeframe: 2 years

Trial details

NCT IDNCT05191186

SponsorAarhus University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-08-01

View on ClinicalTrials.gov More Allergic Rhinitis Due to Grass Pollen trials